Time filter

Source Type

Tian Y.,Nanjing Medical University | Wang K.,Nanjing Medical University | Wang Z.,Nanjing Medical University | Li N.,Third Peoples Hospital of Shenzhen | Ji G.,Nanjing Medical University
Carcinogenesis | Year: 2013

Chronic colonic inflammation is a known risk factor for colorectalcancer (CRC). Glutamine (GLN) supplementation has shownits anti-inflammation benefit in experimental colitis. WhetherGLN is effective in preventing colon carcinogenesis remains tobe investigated. The chemopreventive activity of GLN was evaluatedin the mouse model of dextran sulfate sodium (DSS)/azoxymethane(AOM)-induced colitis-associated CRC in this study. Mice were treated with DSS/AOM and randomized to receiveeither a control diet or GLN-enriched diet intermittently of thestudy. The disease activity index was evaluated weekly. On day80 of the experiment, the entire colon and rectum were processedfor histopathologic examination and further evaluation. Pro-inflammatory mediators and cytokines were measured byenzyme-linked immunosorbent assay, real-time-PCR and westernblot analysis. Here, we show that after GLN-enriched diet, the colitis presented a statistical improvement and tumors burdendecreased significantly. This was accompanied by lower activityof nuclear factor-κB (NF-κB), decreased expression of cyclooxygenase-2 and inducible nitric oxide synthase, lower expression ofcytokines and chemokines as well as reduced proliferation andinduced apoptosis in the colons of colitis-associated CRC mice. Our data demonstrate the protective/preventive effect of GLN inthe progression of colitis-associated CRC, which was correlatedwith a dampening of inflammation and NF-κB activity and with adecrease of inflammatory protein overexpression. © The Author 2013. Published by Oxford University Press. All rights reserved. Source

Zeng W.,Third Peoples Hospital of Shenzhen
Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology | Year: 2013

This study aimed at evaluating the efficacy and safety of a combination treatment of entecavir and Peginterferon alpha-2a for HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads. 60 treatment-naive HBeAg-positive CHB patients with high serum hepatitis B viral loads were enrolled and randomly divided into three groups: group A received Peginterferon alpha-2a monotherapy for 48 weeks (n = 20); group B received entecavir monotherapy for more than 48 weeks (n = 20); group C received Peginterferona alpha-2a combined with entecavir for 12 weeks, then Peginterferon alpha-2a monotherapy for 36 weeks (n = 20). Virological response, ALT normalization, HBeAg and HBsAg seroclearance rate were analysed at the end of 4, 12 and 24 weeks after the treatment. The ratio of undetectable hepatitis B virus (HBV) DNA were 50% and 10%, 95% and 25% and 100% and 30% in group C and group A respectively, 50% and 20%, 95% and 75% and 100% and 90% in group C and group B respectively at the end of 4, 12 and 24 weeks of treatment. The differences were significant between group C and A (Z = -4.6, P < 0.001), group C and B (Z = -2.53, P = 0.0114). ALT normalization rate was significantly lower in group A than that of group C (Z = -2.63, P = 0.0086). HBeAg levels declined more in group C than the other two groups after 24 weeks of treatment. For HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads, combination treament of Peginterferon alpha-2a with entecavir is more effective than Peginterferon alpha-2a monotherapy in virologic response and ALT normalization after 24 weeks of treatment. Source

Zhang X.,Guangdong University of Technology | Yin Y.,Guangdong University of Technology | Guo Y.,Guangdong University of Technology | Fan N.,University of Jinan | And 7 more authors.
Ultrasound in Medicine and Biology | Year: 2015

The viscoelastic properties of the human cornea can provide valuable information for clinical applications such as the early detection of corneal diseases, better management of corneal surgery and treatment and more accurate measurement of intra-ocular pressure. However, few techniques are capable of quantitatively and non-destructively assessing corneal biomechanics invivo. The cornea can be regarded as a thin plate in which the vibration induced by an external vibrator propagates as a Lamb wave, the properties of which depend on the thickness and biomechanics of the tissue. In this study, pulses of ultrasound radiation force with a repetition frequency of 100 or 200Hz were applied to the apex of corneas, and the linear-array transducer of a SonixRP system was used to track the tissue motion in the radial direction. Shear elasticity and viscosity were estimated from the phase velocities of the A0 Lamb waves. To assess the effectiveness of the method, some of the corneas were subjected to collagen cross-linking treatment, and the changes in mechanical properties were validated with a tensile test. The results indicated that the shear modulus was 137±37kPa and the shear viscosity was 3.01±2.45mPa·s for the group of untreated corneas and 1145±267kPa and was 0.16±0.11mPa·s for the treated group, respectively, implying a significant increase in elasticity and a significant decrease in viscosity after collagen cross-linking treatment. This result is in agreement with the results of the mechanical tensile test and with reports in the literature. This initial investigation illustrated the ability of this ultrasound-based method, which uses the velocity dispersion of low-frequency A0 Lamb waves, to quantitatively assess both the elasticity and viscosity of corneas. Future studies could discover ways to optimize this system and to determine the feasibility of using this method in clinical situations. © 2015 World Federation for Ultrasound in Medicine & Biology. Source

Huang J.,Guangdong Medical College | Song G.,Third Peoples Hospital of Shenzhen | Yin Z.,Guangdong Medical College | Luo X.,Guangdong Medical College | Ye Z.,Guangdong Medical College
Modern Rheumatology | Year: 2014

Objectives. Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by new bone formation. Recent evidence suggests that new bone formation in AS may be due to upregulation of Wnt signaling in the osteoblastic pathway secondary to low serum Dickkopf homolog 1 (Dkk-1) levels. And miR-29a orchestrates osteoblast differentiation through direct targeting and negative regulation of Dkk-1. Methods. We initially validated the expression levels of miR-29a in the peripheral blood mononuclear cells (PBMCs) of AS patients (n = 30), rheumatoid arthritis (RA) patients (n = 30) and healthy controls (n = 30) using real-time quantitative reverse transcription PCR (qRT-PCR). Correlation analysis was assessed between miR-29a level in PBMCs of AS patients and disease activity indexes, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis function index (BASFI) and modified Stoke ankylosing spondylitis spinal score (mSASSS). Results. Significantly higher expression of miR-29a was observed in PBMCs of AS patients (Ct 9.18 ± 1.96) compared with that in RA patients (10.97 ± 0.70, p < 0.001) and healthy controls (Ct 11.45 ± 1.23, p < 0.001). There was no significant difference between RA patients and healthy controls in miR-29a expression (p > 0.05). Elevated miR-29a expression is not correlated with disease activity index (p > 0.05). A weak correlation was found between elevated miR-29a expression and mSASSS (r = -0.393, p = 0.032). Conclusions. We report for the first time elevated miR-29a expression in PBMCs of patients with ankylosing spondylitis, and miR-29a might be used as a useful diagnostic marker in new bone formation but cannot reflect disease activity. © 2014 Japan College of Rheumatology. Source

Chen W.,Jinan University | Tan K.,Ningbo No. 2 Hospital | Huang J.,Jinan University | Yu X.,Jinan University | And 5 more authors.
Connective Tissue Research | Year: 2014

Objectives: Our aim in this study was to identify and examine the differential expression of microRNAs in patients with systemic lupus erythematosus (SLE). Methods: We employed high-quality, high-throughput Solexa sequencing to clone and identify microRNAs in SLE patients and a control group. Results: From the sequencing data, we identified numerous microRNAs displaying significantly different levels of expression in patients with SLE and in healthy controls. The 212 and 199 microRNAs were upregulated and downregulated, respectively. Only 61 novel microRNAs exhibited significantly different levels of expression in the two groups. The target genes of the novel microRNAs identified in the SLE group were found to have cell metabolism functions. We also analyzed the chromosomal locations of the microRNAs with high level of expression between the two groups. A profile comparison revealed that the majority of transcripts were expressed at a similar level. The functional classes of the most abundant microRNAs were equally represented on each chromosome. Conclusion: We identified novel and known microRNAs significantly enhancing our understanding of the microRNA expression profiles of SLE patients. These data also provide insight into the function of microRNAs in SLE and provide new strategies for future therapies. © 2014 Informa Healthcare USA, Inc. Source

Discover hidden collaborations